As CD98 complements the dominant suppression of integrin, and the transmembrane and cytoplasmic domains of CD98 are necessary and sufficient for interactions with β1-integrin, we speculate that isolated CD98-ICD would similarly suppress β1-integrin activation and inhibit the malignant behaviors of cancer cells. The gene discussed is SLC3A2; the disease is cancer.